2186 (2186) Fair Value & Analysis

Healthcare · Market cap HK$7.3B

2 2186 2186 · HK

PriceHK$1.86

Fair ValueHK$3.93

Upside+111.3%

Quality36/100

Watch 2186 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$2.95 – HK$4.92

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −15.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.78 – HK$4.46 · fair‑value band HK$2.95 – HK$4.92 · the HK$1.86 price screens below the HK$3.93 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2186 (2186) currently trades at HK$1.86, while our model-based Fair Value estimate is HK$3.93 — implying the stock looks roughly 111.3% undervalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 2186 generated revenue of HK$6.3B at a net margin of 9.8%. Revenue grew 4.7% year over year. It earns a return on equity of 4.1%. Net debt stands at HK$4.9B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$6.3B

Revenue growth (YoY) +4.7%

Net margin 9.8%

Return on equity 4.1%

Free cash flow HK$780M FY2025

P/E ratio 13.1

More key figures

Operating margin 19.4%

EPS (TTM) HK$0.0800

EPS growth (YoY) +240%

Net debt HK$4.9B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2186 reported revenue of HK$6.3B in FY2025 versus HK$5.2B in FY2021, a compound +4.9%/yr. Reported net income was HK$619M in FY2025.

Revenue +4.9%/yr

FY21 HK$5.2B

FY22 HK$6.0B

FY23 HK$6.1B

FY24 HK$6.1B

FY25 HK$6.3B

Net income

FY21 −HK$134M

FY22 HK$605M

FY23 HK$533M

FY24 HK$472M

FY25 HK$619M

Is 2186 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,786	₹991.46	-44%
Zoetis Inc Z1TS34	R$25.93	R$19.70	-24%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2186 (2186) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$3.93 versus a price of HK$1.86 — about +111% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2186?

Our model-based fair value for 2186 is HK$3.93 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.86.

What is the quality score of 2186?

2186 has a Quality Score of 36/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2186 (2186)?

2186 reported trailing-twelve-month revenue of about HK$6.3B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2186?

The net profit margin of 2186 is about 9.8%, meaning it keeps roughly 9.8% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.